Victory Capital Management
SUPN icon

Victory Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Victory Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Sell
391,075
-111,331
-22% -$5.35M 0.01% 936
2026
Q1 		$26M Sell
502,406
-23,814
-5% -$1.21M 0.02% 774
2025
Q4 		$26.2M Sell
526,220
-33,615
-6% -$1.63M 0.01% 785
2025
Q3 		$26.8M Sell
559,835
-191,708
-26% -$7.72M 0.02% 798
2025
Q2 		$23.7M Buy
751,543
+79,025
+12% +$2.53M 0.02% 815
2025
Q1 		$22M Sell
672,518
-41,803
-6% -$1.48M 0.02% 778
2024
Q4 		$25.8M Sell
714,321
-28,550
-4% -$1.01M 0.03% 745
2024
Q3 		$23.2M Buy
742,871
+7,833
+1% +$244K 0.02% 796
2024
Q2 		$19.7M Buy
735,038
+87,200
+13% +$2.53M 0.02% 819
2024
Q1 		$22.1M Sell
647,838
-42,560
-6% -$1.27M 0.02% 777
2023
Q4 		$20M Sell
690,398
-20,771
-3% -$551K 0.02% 776
2023
Q3 		$19.6M Buy
711,169
+52,468
+8% +$1.6M 0.02% 763
2023
Q2 		$19.8M Sell
658,701
-2,035
-0.3% -$71.2K 0.02% 777
2023
Q1 		$23.9M Sell
660,736
-25,102
-4% -$965K 0.03% 705
2022
Q4 		$24.5M Sell
685,838
-91,631
-12% -$3.18M 0.03% 698
2022
Q3 		$26.3M Sell
777,469
-7,251
-0.9% -$236K 0.03% 687
2022
Q2 		$22.7M Sell
784,720
-54,882
-7% -$1.57M 0.03% 778
2022
Q1 		$26.9M Sell
839,602
-7,641
-0.9% -$234K 0.03% 772
2021
Q4 		$24.7M Sell
847,243
-19,507
-2% -$592K 0.02% 833
2021
Q3 		$23.1M Buy
866,750
+227,872
+36% +$6.12M 0.02% 832
2021
Q2 		$19.7M Buy
638,878
+217,931
+52% +$6.68M 0.02% 904
2021
Q1 		$11M Sell
420,947
-7,007
-2% -$196K 0.01% 1117
2020
Q4 		$10.8M Sell
427,954
-58,891
-12% -$1.27M 0.01% 1086
2020
Q3 		$10.1M Buy
486,845
+459,351
+1,671% +$10.4M 0.01% 1042
2020
Q2 		$653K Buy
27,494
+1,914
+7% +$42.3K ﹤0.01% 1895
2020
Q1 		$460K Sell
25,580
-2,888
-10% -$60.7K ﹤0.01% 1869
2019
Q4 		$675K Buy
28,468
+6,845
+32% +$166K ﹤0.01% 1880
2019
Q3 		$594K Buy
21,623
+19,604
+971% +$581K ﹤0.01% 1831
2019
Q2 		$67K Sell
2,019
-3,507
-63% -$120K ﹤0.01% 1696
2019
Q1 		$194K Sell
5,526
-2,010
-27% -$74.8K ﹤0.01% 1574
2018
Q4 		$250K Buy
7,536
+296
+4% +$12.7K ﹤0.01% 1515
2018
Q3 		$365K Buy
7,240
+3,080
+74% +$152K ﹤0.01% 1496
2018
Q2 		$249K Buy
4,160
+570
+16% +$29.5K ﹤0.01% 1583
2018
Q1 		$164K Buy
3,590
+846
+31% +$35.3K ﹤0.01% 1642
2017
Q4 		$109K Buy
2,744
+239
+10% +$9.44K ﹤0.01% 1680
2017
Q3 		$100K Sell
2,505
-936
-27% -$40.5K ﹤0.01% 1696
2017
Q2 		$148K Buy
3,441
+517
+18% +$18.4K ﹤0.01% 1589
2017
Q1 		$92K Buy
2,924
+190
+7% +$5.09K ﹤0.01% 1665
2016
Q4 		$69K Sell
2,734
-68
-2% -$1.52K ﹤0.01% 1665
2016
Q3 		$69K Buy
2,802
+253
+10% +$5.73K ﹤0.01% 1653
2016
Q2 		$52K Buy
2,549
+1,111
+77% +$19.7K ﹤0.01% 1511
2016
Q1 		$22K Sell
1,438
-1,046
-42% -$13.6K ﹤0.01% 1606
2015
Q4 		$33K Sell
2,484
-78
-3% -$1.21K ﹤0.01% 1619
2015
Q3 		$36K Buy
+2,562
New +$47.6K ﹤0.01% 1552

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Victory Capital Management's SUPN Position: Q2 2026 in Review

Victory Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 22% in Q2 2026, selling an estimated $5.35M and leaving 391,075 shares worth $18.2M. The position accounts for 0.01% of the portfolio, ranked #936.

Victory Capital Management first reported a position in SUPN in Q3 2015 and has held it in 44 quarters since. The position peaked at $26.9M in Q1 2022. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Victory Capital Management held 391,075 shares of Supernus Pharmaceuticals worth $18.2M as of Q2 2026.
  • Victory Capital Management sold 111,331 Supernus Pharmaceuticals shares in Q2 2026, an estimated $5.35M.
  • Supernus Pharmaceuticals made up 0.01% of Victory Capital Management's portfolio in Q2 2026, its #936 holding.
  • Victory Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2015 and has held it in 44 quarters since.
  • Victory Capital Management's Supernus Pharmaceuticals position peaked at $26.9M in Q1 2022.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.